Sign up Australia
Proactive Investors - Run By Investors For Investors

Isodiol’s BSPG subsidiary receives approval from UK regulators to manufacture CBD

Isodiol said the greenlight from the Medicines and Healthcare Products Regulatory Agency means it can now export its CBD around the world
cbd oil and cannabis flower
CBD is a non-psychoactive cannabinoid found in cannabis which has been touted as a possible treatment for things like pain and stress

BSPG Laboratories, a subsidiary of CBD consumer products maker Isodiol International Inc (CSE:ISOL; OTC:ISOLF), has received approval from UK regulators to manufacture cannabidiol (CBD).

Cannabidiol is a non-psychoactive cannabinoid found in cannabis, and research has suggested it could have several medical benefits such as pain and stress relief.

A first in the industry

With the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), BSPG’s natural CBD isolate can now be exported around the world, subject to pharmaceutical regulations.

“This approval validates the consistent quality of our pure, natural CBD isolate and the patented manufacturing processes,” said Isodiol’s Chief Executive Marcos Agramont.

“This event is a first in the industry and now enables Isodiol to focus on the development of CBD based drugs that will address a myriad of conditions that are affecting so many people around the world.”

He added: “With this approval, we will now rapidly advance our pharmaceutical and drug development divisions.”

Isodiol is currently building a state-of-the-art manufacturing facility which is expected to be up-and-running in the first quarter of 2019.

Once it is completed, the company expects to be able to produce around 20,000 kg of CBD each year, which will help it to “serve this newly created demand for CBD drug development, approved pharmaceutical applications, research, clinical studies, and clinical trials”.

Isodiol shares were down 4.7% to C$0.82 on Thursday morning.

View full ISOL profile View Profile

Isodiol International Timeline

Related Articles

1536105601_cobalt.jpg
September 05 2018
During the completion of its phase 1 exploration program at Bujagali and associated infill sampling, M2 Cobalt discovered six additional large-scale anomalies with highly anomalous rock and soil samples

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use